Memantine hydrochloride is a raw material. It should be prescribed by experienced doctors in the diagnosis and treatment of Alzheimer's dementia and guided by patients. Treatment can only begin when there are caregivers around the patient who regularly supervise the patient's medication. Dementia should be diagnosed in accordance with current diagnostic criteria and guidelines.
Memantine is a medication used to treat moderate-to-severe Alzheimer's disease. It is less preferred than acetylcholinesterase inhibitors such as donepezil. Treatment should only be continued if beneficial effects are seen. It is taken by mouth.
Memantine was approved for medical use in the United States in 2003. It is available as a generic medication. In 2017, it was the 149th most commonly prescribed medication in the United States, with more than four million prescriptions
Memantine is clinically used for the treatment of moderate to severe senile dementia and parkinsonism syndrome. It is a new type of anti-senile dementia drug and can be used for the treatment of moderate to severe senile dementia.
Memantine is used to treat moderate-to-severe Alzheimer's disease, especially for people who are intolerant of or have a contraindication to AChE (acetylcholinesterase) inhibitors.One guideline recommends memantine or an AChE inhibitor be considered in people in the early-to-mid stage of dementia.
Memantine has been associated with a modest improvement; with small positive effects on cognition, mood, behavior, and the ability to perform daily activities in moderate-to-severe Alzheimer's disease. There does not appear to be any benefit in mild disease.
Memantine when added to donepezil in those with moderate-to-severe dementia resulted in "limited improvements" in a 2017 review. The UK National Institute of Clinical Excellence (NICE) issued guidance in 2018 recommending consideration of the combination of memantine with donepezil in those with moderate-to-severe dementia. Effects in autism are unclear. Recent scientific journal reports are showing guarded promise with severe obsessive compulsive disorder.
ພວກເຮົາມີໂຮງງານທີ່ມີຄຸນນະພາບສູງຫຼາຍທີ່ມີການຮ່ວມມືຢ່າງເລິກເຊິ່ງ, ເຊິ່ງສາມາດໃຫ້ທ່ານຜະລິດຕະພັນທີ່ມີຄຸນນະພາບສູງແລະລາຄາທີ່ແຂ່ງຂັນ. ແລະພວກເຮົາຍັງສາມາດໃຫ້ສ່ວນຫຼຸດສໍາລັບການຊື້ຈໍານວນຫລາຍ.ແລະພວກເຮົາຮ່ວມມືກັບບໍລິສັດຂົນສົ່ງສິນຄ້າມືອາຊີບຈໍານວນຫຼາຍ, ສາມາດຈັດສົ່ງຜະລິດຕະພັນໄດ້ຢ່າງປອດໄພແລະກ້ຽງກັບມືຂອງທ່ານ. ເວລາສົ່ງແມ່ນປະມານ 3-20 ມື້ຫຼັງຈາກຢືນຢັນການຈ່າຍເງິນ.
ລາຍການ |
Requirements |
Test Results |
appearance |
White or almost white crystalline powder |
White crystalline powder |
Identification |
IR |
Comply |
Related substance |
1-methyladamantane ≤0.3% 1,3,5 -trimethyladamantane ≤0.3% Unknow impuritiy ≤0.1% Total impurity ≤0.5% |
0.13% 0.14% <0.1% <0.4% |
Residue on ignition |
≤0.1% |
0.06% |
Heavy matal |
≤10ppm |
<10ppm |
Loss on drying |
≤0.5% |
0.29% |
ວິເຄາະ |
98.5-101.0% |
99.13% |
Residual Solvents |
Ethyl Acetat: ≤0.5% Ethanol: ≤0.5% |
0.08% 0.12% |
PH |
4.5-5.5 |
5.3 |
Microbial Limits |
Max 5*102 aerobes and fungl per 1g E. Coli: Negative Salmonella: Negative
|
Pass |
Size of distributed particles |
Pass 100μ m |
Conforms |
ສະຫຼຸບ |
Meet the requirements |
Memantine is a medication used to treat moderate-to-severe Alzheimer's disease. It is less preferred than acetylcholinesterase inhibitors such as donepezil. Treatment should only be continued if beneficial effects are seen. It is taken by mouth.
Memantine was approved for medical use in the United States in 2003. It is available as a generic medication. In 2017, it was the 149th most commonly prescribed medication in the United States, with more than four million prescriptions
Memantine HCl is the HCl form of Memantine. Memantine is a well- known neuroprotective drug used for the treatment of Alzheimer's disease. It is believed to be the first neuroprotective drug that has achieve clinical approval by US FDA as well as European.
The development of Alzheimer's disease involves the misfolded mutant proteins such as β-amyloid peptide (Aβ, particularly Aβ1−42). These misfolded mutant protein can increase the NMDA response and further cause severe excitotoxicity.
Memantine suppresses this process through acting as the antagonist of the N-methyl-d- aspartate-sensitive glutamate receptor (NMDARs).
Memantine is also under investigation as a potential treatment for other kind of neurodegenerative disorders such as HIV-associated dementia, neuropathic pain, glaucoma, depression, Huntington's disease, ALS and movement disorders, among other.
1. ເຈົ້າເປັນໂຮງງານຫຼືບໍລິສັດການຄ້າບໍ?
ພວກເຮົາແມ່ນ compnay ອຸດສາຫະກໍາປະສົມປະສານແລະການຄ້າ, ການສະຫນອງການບໍລິການທີ່ຢຸດດຽວ.OEM ສາມາດໄດ້ຮັບການຍອມຮັບ.
2. ເຈົ້າໃຫ້ຕົວຢ່າງບໍ? ມັນບໍ່ເສຍຄ່າຫຼືພິເສດບໍ?
ຕົວຢ່າງຟຣີ.ຄ່າທໍານຽມການຂົນສົ່ງຂອງຕົວຢ່າງຈໍາເປັນຕ້ອງຈ່າຍໂດຍຂ້າງຂອງທ່ານ.
3. ທ່ານມີໃບຢັ້ງຢືນທີ່ກ່ຽວຂ້ອງກັບການຄວບຄຸມຄຸນນະພາບບໍ?
ການຢັ້ງຢືນ ISO 9001: 2008 ເພື່ອຮັບປະກັນຄຸນນະພາບ.
4. ຂ້ອຍຄວນຈັດຫາຫຍັງເພື່ອໃຫ້ໄດ້ໃບສະເໜີລາຄາ?
Pls ແຈ້ງພວກເຮົາກ່ຽວກັບປະເພດຜະລິດຕະພັນທີ່ທ່ານຕ້ອງການ, ຈໍານວນການສັ່ງຊື້, ທີ່ຢູ່ແລະຄວາມຕ້ອງການສະເພາະ.
5. ເຈົ້າມັກວິທີຈ່າຍເງິນແບບໃດ? ປະເພດໃດແດ່ທີ່ຍອມຮັບ?
ເງື່ອນໄຂການຈັດສົ່ງທີ່ຍອມຮັບ: FOB, CFR, CIF, EXW;
ສະກຸນເງິນທີ່ຍອມຮັບ: USD;
ປະເພດການຈ່າຍເງິນທີ່ຍອມຮັບ: T / T, Western Union; Paypal, ປະກັນການຄ້າ.
ພາສາເວົ້າ: ພາສາອັງກິດ.
ປະເພດຜະລິດຕະພັນ